AFFILIATIONS
1 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
2 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
3 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
4 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
5 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
6 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
7 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
8 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
9 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
10 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
11 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
12 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
13 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine,, HANGZHOU, China
ABSTRACT
Background: Philadelphia chromosome–positive (Ph?) acute lymphoblastic leukemia (ALL) accounts for 20–30% of adult B-cell ALL and up to 50% in patients aged ≥60 years. Low-intensity induction by combining BCR::ABL1 tyrosine kinase inhibitors (TKIs) with glucocorticoids achieves complete remission (CR) in >95% of newly diagnosed patients. However, ABL1 kinase domain mutations—particularly the gatekeeper T315I mutation—frequently emerge during early TKIs therapy. Third-generation TKIs—olverembatinib and ponatinib—potently inhibit both wild-type and mutant BCR::ABL1, including T315I, offering a pivotal therapeutic advance. Yet, prospective or large-scale retrospective comparisons of third- versus first-/second-generation TKIs as frontline therapy in newly diagnosed adult Ph? ALL remain limited.
Objective: To compare the efficacy of third-generation TKIs (olverembatinib or ponatinib) versus first- (imatinib) or second-generation TKIs (dasatinib, nilotinib, or flumatinib) as induction therapy in newly diagnosed adult Ph? ALL.
Methods: We conducted a single-center, retrospective cohort study included consecutive adults (≥16 years) with newly diagnosed Ph? ALL treated at our center from 2019 to 2025. Primary endpoint: Complete molecular response (CMR), defined as morphologic complete remission (CR) with BCR::ABL1 transcript negativity by quantitative reverse transcription PCR (RT-qPCR) in bone marrow aspirate collected at the end of induction therapy (cycle 3). Secondary endpoints: 2-year event-free survival (EFS) and overall survival (OS).
Results: Among 385 enrolled patients (median age 48 years; 50.1% female), early death rate was 1.0% (4/385); 381 (99.0%) achieved morphologic CR. Patients were stratified by frontline TKI generation: third-generation (n=142), second-generation (n=208), and first-generation (n=31). At month 3, CMR rates were 91.6%, 62.5%, and 35.4%, respectively (P<0.001); 2-year EFS was 80.1%, 68.3%, and 48.2% (P<0.001); and 2-year OS was 83.7%, 82.4%, and 74.3% (P=0.77).
Conclusions: Frontline third-generation TKIs significantly improve early MRD? CR and 2-year EFS versus earlier-generation TKIs in adult Ph? ALL. Although OS differences did not reach statistical significance—potentially due to limited follow-up duration and effective salvage therapies. Our data support prioritizing third-generation TKIs in initial treatment strategies, especially for high-risk patients.
DISCLOSURES
Yinjun Lou, MD: No relevant conflicts of interest to declare.